New Paper Published in The Journal of Liquid Biopsy A B S T R A C T Background: Cerebrospinal fluid (CSF) is a relatively accessible
GTC highlights Liquid Trace® CSF testing as NCCN updates support CSF-based molecular profiling for inoperable gliomas and glioblastomas.
Lake Forest, CA — December 2, 2025 — Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for
Liquid biopsies are a rapidly evolving diagnostic technology with numerous labs offering commercially available tests today. Most labs have taken an approach of cell-free (cfDNA)
Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of
GTC presented abstracts at ASH 2022 GTC’s posters from 2022 Convention of American Society of Hematology are now available to be downloaded. Please reach out
In partnership with Anthology Diagnostics and Key Genomics, GTC presented four abstracts at ASH 2021 GTC’s posters from 2021 Convention of American Society of Hematology
GTC scientists collaborate with the NIH on a study just published in the Journal of Clinical Oncology. The publication is titled: Prediction of outcome in
Jul 23, 2020 | John Gilmore NEW YORK – As part of plans to establish a country-wide network of labs for minimizing the cost of
John Theurer Cancer Center to Establish Next Generation Sequencing Laboratory for Precision Genomic Profiling of Cancers, Adapting Testing Developed for DNA and RNA IRVINE, Calif.
